Screening for EGFR-Positive Lung Cancer Using a New Blood Test in East Asian and Latinx Adults Aged 40 to 80

What this Trial Is About

Researchers are evaluating a new blood test called the Circulating Tumor DNA ctDNA Assay to screen for Epidermal Growth Factor Receptor EGFR positive lung cancer among East Asian and Latinx adults aged 40 to 80 who are at risk but cannot undergo regular lung cancer screening. This test focuses on detecting specific EGFR gene changes that make up most EGFR mutations in lung cancer. The study aims to assess whether this blood test can identify lung cancer before symptoms appear. Participants provide blood samples that are tested using the investigational ctDNA assay. If the test shows positive or unclear results, further confirmation is done through CLIA testing, followed by a lung CT scan if confirmed. Depending on CT scan results, participants may receive referrals for additional evaluation or have repeat scans after 12 months. Optional activities include a one-time survey on lung cancer screening perceptions, virtual focus groups, and blood banking studies. During the study, participants undergo eligibility screening, blood sample collection, and complete a baseline questionnaire. They may also participate in optional surveys or focus groups. Researchers monitor detection rates of lung cancer over two years, turnaround time for test results, recruitment acceptability, and challenges in collecting samples. Participants will be informed of their results and followed accordingly, with the study expected to run until 2030.

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations